

Company Number: 701914

**Walkers Pharmacy Ltd**  
**Abridged Unaudited Financial Statements**  
**for the financial year ended 30 April 2025**

# Walkers Pharmacy Ltd

## CONTENTS

	<b>Page</b>
Directors and Other Information	3
Directors' Responsibilities Statement	4
Accountants' Report	5
Statement of Financial Position	6
Statement of Changes in Equity	7
Notes to the Financial Statements	8 - 12

**Walkers Pharmacy Ltd**  
**DIRECTORS AND OTHER INFORMATION**

<b>Directors</b>	Conor Martin Ann Marie Martin
<b>Company Secretary</b>	Conor Martin
<b>Company Number</b>	701914
<b>Registered Office</b>	Medical Hall Main St Enfield Co Meath
<b>Business Address</b>	Main St Enfield Co Meath A83 Y299
<b>Accountants</b>	Michael McDonnell & Company Accountants Limited Chartered Certified Accountants Main Street Enfield Co.Meath

# Walkers Pharmacy Ltd

## DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 April 2025

The directors made the following statement in respect of the unaudited financial statements:

### "General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Michael McDonnell & Company Accountants Limited, (Chartered Certified Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 April 2025."

**Signed on behalf of the board**

**Conor Martin**  
Director

**Ann Marie Martin**  
Director

**20 January 2026**

**Walkers Pharmacy Ltd**  
**CHARTERED CERTIFIED ACCOUNTANTS REPORT**  
**to the Board of Directors on the Compilation of the unaudited Abridged financial statements of Walkers Pharmacy Ltd**  
**for the financial year ended 30 April 2025**

In accordance with our engagement letter dated 4 November 2025 and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled for your approval the abridged financial statements of the company for the financial year ended 30 April 2025 as set out on pages 6 to 12 which comprise the Statement of Financial Position, the Statement of Changes in Equity and the related notes from the company's accounting records and information and explanations you have given to us.

This report is made solely to the Board of Directors of Walkers Pharmacy Ltd, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's Board of Directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and its Board of Directors, as a body, for our work or for this report.

As a firm regulated by the Association of Chartered Certified Accountants our work will be carried out in accordance with the Technical Factsheet 163 Audit Exempt Companies - ACCA Accounts Preparation Report and ISRS 4410 International Standard on Related Services -Compilation Engagements. In carrying out this engagement we have complied with the ethical guidance laid down by the association relating to members undertaking the compilation of financial statements.

You have acknowledged on the Statement of Financial Position for the year ended 30 April 2025 your duty to ensure that Walkers Pharmacy Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and loss of Walkers Pharmacy Ltd. You consider that Walkers Pharmacy Ltd is exempt from the statutory audit requirement for the financial year.

We have not been instructed to carry out an audit or a review of the abridged financial statements of Walkers Pharmacy Ltd. For this reason, we have not verified the adequacy, accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory abridged financial statements.

**Michael McDonnell**  
**for and on behalf of**  
**MICHAEL MCDONNELL & COMPANY ACCOUNTANTS LIMITED**  
Chartered Certified Accountants and Statutory Auditors  
Main Street  
Enfield  
Co.Meath

**20 January 2026**

# Walkers Pharmacy Ltd

## STATEMENT OF FINANCIAL POSITION

as at 30 April 2025

	Notes	2025 €	2024 €
<b>Non-Current Assets</b>			
Intangible assets	5	1,140,000	1,710,000
Property, plant and equipment	6	79,194	86,514
		<u>1,219,194</u>	<u>1,796,514</u>
<b>Current Assets</b>			
Stocks	7	324,493	322,105
Debtors	8	177,641	152,612
Cash and cash equivalents		1,361,199	930,071
		<u>1,863,333</u>	<u>1,404,788</u>
<b>Creditors: amounts falling due within one year</b>	9	<u>(222,393)</u>	<u>(160,249)</u>
<b>Net Current Assets</b>		<u>1,640,940</u>	<u>1,244,539</u>
<b>Total Assets less Current Liabilities</b>		<u>2,860,134</u>	<u>3,041,053</u>
<b>Capital and Reserves</b>			
Called up share capital presented as equity		3,469,600	3,469,600
Retained earnings		(609,466)	(428,547)
<b>Equity attributable to owners of the company</b>		<u>2,860,134</u>	<u>3,041,053</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

We as Directors of Walkers Pharmacy Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 359 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

**Approved by the board on 20 January 2026 and signed on its behalf by:**

**Conor Martin**  
Director

**Ann Marie Martin**  
Director

**Walkers Pharmacy Ltd**  
**STATEMENT OF CHANGES IN EQUITY**

as at 30 April 2025

	<b>Called up share capital €</b>	<b>Retained earnings €</b>	<b>Total €</b>
<b>At 1 May 2023</b>	3,469,600	(199,011)	3,270,589
Loss for the financial year	-	(229,536)	(229,536)
<b>At 30 April 2024</b>	3,469,600	(428,547)	3,041,053
Loss for the financial year	-	(180,919)	(180,919)
<b>At 30 April 2025</b>	<b>3,469,600</b>	<b>(609,466)</b>	<b>2,860,134</b>

# Walkers Pharmacy Ltd

## NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 1. General Information

Walkers Pharmacy Ltd is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 701914. The registered office of the company is Medical Hall, Main St, Enfield, Co Meath. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

### 2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

#### Statement of compliance

The financial statements of the company for the financial year ended 30 April 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

#### Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

#### Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

#### Goodwill

Purchased goodwill arising on the acquisition of a business represents the excess of the acquisition cost over the fair value of the identifiable net assets including other intangible fixed assets when they were acquired. Purchased goodwill is capitalised in the Statement of Financial Position and amortised on a straight line basis over its economic useful life of 5 years, which is estimated to be the period during which benefits are expected to arise. On disposal of a business any goodwill not yet amortised is included in determining the profit or loss on sale of the business.

#### Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	- 12.5% Straight line
----------------------------------	-----------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

#### Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

**Walkers Pharmacy Ltd**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**  
for the financial year ended 30 April 2025

**Trade and other debtors**

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

**Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Creditors.

**Borrowing costs**

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

**Trade and other creditors**

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

**Employee benefits**

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

**Taxation and deferred taxation**

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Statement of Financial Position date.

**Government grants**

Capital grants received and receivable are treated as deferred income and amortised to the Income Statement annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Income Statement when received.

**Foreign currencies**

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Statement of Financial Position date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income Statement.

**Ordinary share capital**

The ordinary share capital of the company is presented as equity.

## Walkers Pharmacy Ltd

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

<b>3. Operating loss</b>	<b>2025</b>	2024
	€	€
<b>Operating loss is stated after charging/(crediting):</b>		
Amortisation of intangible assets	<b>570,000</b>	570,000
Depreciation of property, plant and equipment	<b>15,120</b>	14,145
Loss on foreign currencies	<b>1,101</b>	362
Government grants received	<b>(9,000)</b>	-
	<u><u>          </u></u>	<u><u>          </u></u>

## 4. Employees

The average monthly number of employees, including directors, during the financial year was 11, (2024 - 12).

	<b>2025</b>	2024
	Number	Number
Directors	<b>1</b>	2
Shop Staff	<b>10</b>	10
	<u>          </u>	<u>          </u>
	<b>11</b>	12
	<u><u>          </u></u>	<u><u>          </u></u>

## 5. Intangible assets

	<b>Goodwill</b>	<b>Total</b>
	€	€
<b>Cost</b>		
At 1 May 2024	2,850,000	2,850,000
	<u>          </u>	<u>          </u>
At 30 April 2025	2,850,000	2,850,000
	<u>          </u>	<u>          </u>
<b>Provision for diminution in value</b>		
At 1 May 2024	1,140,000	1,140,000
Charge for financial year	570,000	570,000
	<u>          </u>	<u>          </u>
At 30 April 2025	1,710,000	1,710,000
	<u>          </u>	<u>          </u>
<b>Net book value</b>		
At 30 April 2025	<b>1,140,000</b>	<b>1,140,000</b>
	<u><u>          </u></u>	<u><u>          </u></u>
At 30 April 2024	1,710,000	1,710,000
	<u><u>          </u></u>	<u><u>          </u></u>

## Walkers Pharmacy Ltd

# NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 April 2025

### 6. Property, plant and equipment

	Fixtures, fittings and equipment €	Total €
<b>Cost</b>		
At 1 May 2024	113,159	113,159
Additions	7,800	7,800
	<u>120,959</u>	<u>120,959</u>
<b>Depreciation</b>		
At 1 May 2024	26,645	26,645
Charge for the financial year	15,120	15,120
	<u>41,765</u>	<u>41,765</u>
<b>Net book value</b>		
At 30 April 2025	<u><b>79,194</b></u>	<u><b>79,194</b></u>
At 30 April 2024	<u>86,514</u>	<u>86,514</u>

### 7. Stocks

	2025 €	2024 €
Finished goods and goods for resale	<u><b>324,493</b></u>	<u>322,105</u>

The replacement cost of stock did not differ significantly from the figures shown.

### 8. Debtors

	2025 €	2024 €
Trade debtors	<b>160,336</b>	127,279
Directors' current accounts	<b>37</b>	-
Taxation	<b>17,268</b>	25,333
	<u><b>177,641</b></u>	<u>152,612</u>

### 9. Creditors

<b>Amounts falling due within one year</b>	2025 €	2024 €
Amounts owed to credit institutions	(31)	30
Trade creditors	<b>193,852</b>	134,804
Amounts owed to group undertakings	<b>50</b>	50
Taxation	<b>23,646</b>	20,489
Other creditors	<b>(124)</b>	(124)
Accruals	<b>5,000</b>	5,000
	<u><b>222,393</b></u>	<u>160,249</u>

### 10. Income Statement

	2025 €	2024 €
At 1 May 2024	<b>(428,547)</b>	(199,011)
Loss for the financial year	<b>(180,919)</b>	(229,536)
	<u><b>(609,466)</b></u>	<u>(428,547)</u>

**Walkers Pharmacy Ltd**  
**NOTES TO THE ABRIDGED FINANCIAL STATEMENTS**

for the financial year ended 30 April 2025

**11. Capital commitments**

The company had no material capital commitments at the financial year-ended 30 April 2025.

<b>12. Directors' remuneration</b>	<b>2025</b>	2024
	<b>€</b>	<b>€</b>
Remuneration	<b>40,700</b>	44,231
	<u><u>          </u></u>	<u><u>          </u></u>

**13. Related party transactions**

The company has availed of the exemption under FRS 102 Section 1A in relation to the disclosure of transactions with group undertakings.

**14. Parent company**

The company regards Enfield Pharmacy Limited as its parent company.

**15. Controlling interest**

The company is controlled by Enfield Pharmacy Limited which in turn is controlled by Conor Martin. Conor Martin is the ultimate controlling party of both Enfield Pharmacy Limited and Walkers Pharmacy Limited.

**16. Events After the End of the Reporting Period**

There have been no significant events affecting the company since the financial year-end.

**17. Approval of financial statements**

The financial statements were approved and authorised for issue by the board of directors on 20 January 2026.